QGENQGENHealthcare · Diagnostics & Research

QGEN Stock Forecast: QIAGEN NV Price Predictions for 2026-2027

Last close, 20 Nov 2026
$49
−0.66% on the day

The 12 Wall Street analysts covering QIAGEN NV hold a median 12-month price target of $52 — +5.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 92 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$10.2B
Ticker Nerd rank
92/ 100
Median analyst target
$52
Analysts covering
12
Revenue$535.0M+0.3% y/y
Operating income$140.8M
Net income$103.4M
Free cash flow$157.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.2%
1M
+0.8%
YTD
+5.1%
1Y
+8.9%
From 52W high
−10.6%
From 52W low
+52.4%
$32
$55
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores QIAGEN NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
92/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Value
94
Issuance
91
Revisions
80
Quality
75
Momentum
66
Accruals
65
Growth
47

Volatility (98): The share price has been relatively steady.

Growth (47): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

QGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$35$40$45$50$55Jan 26Apr 26Jul 26Oct 26QGENHigh $53Median $52Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
1
Buy
11
Hold
0
Sell
$40
Low
$52
Median
$53
High

The green dot is the last close — the median target sits +5.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
13 Nov 2026UBSMaintainsNeutral$48 → $50
28 Oct 2026BarclaysDowngradeEqual-Weight$55 → $53
26 Oct 2026CitigroupMaintainsNeutral$45 → $52
22 Oct 2026BairdMaintainsOutperform$50 → $52
22 Oct 2026JP MorganDowngradeNeutral$55 → $52
14 Oct 2026JP MorganMaintainsOverweight$50 → $55
6 Oct 2026BarclaysUpgradeOverweight$40 → $55
9 Sept 2026UBSMaintainsNeutral$52 → $47
10 Aug 2026CitigroupMaintainsNeutral$38 → $45
7 Aug 2026BarclaysMaintainsEqual-Weight$38 → $40
7 Aug 2026JP MorganMaintainsOverweight$45 → $50
23 June 2026Morgan StanleyUpgradeOverweight$40 → $42
18 May 2026StifelMaintainsHold—
7 May 2026TD CowenMaintainsHold—
29 Apr 2026BairdUpgradeOutperform—
29 Apr 2026BarclaysMaintainsEqual-Weight—
29 Apr 2026CitigroupMaintainsNeutral—
29 Apr 2026JP MorganMaintainsOverweight—
14 Apr 2026BarclaysDowngradeEqual-Weight—
13 Mar 2026Deutsche BankUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for QGEN.

Market Radar

This page is one stock. Monday covers all of them.

QGEN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

QGEN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, QIAGEN NV returned +8.9% against +6.9% for the S&P 500, dividends included.

QGEN vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26QGENS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

QGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+2.4%
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
26.7×

Cheaper than 33% of US stocks

Price / sales
4.8×

Cheaper than 22% of US stocks

Price / book
2.9×

Cheaper than 31% of US stocks

EV / EBITDA
14.7×

Cheaper than 35% of US stocks

Growth & margins
Revenue growth (YoY)
2.9%

Higher than 35% of US stocks

Earnings growth (YoY)
−18.8%

Higher than 21% of US stocks

Gross margin
63.6%

Higher than 77% of US stocks

Operating margin
26.7%

Higher than 85% of US stocks

Net margin
18.2%

Higher than 79% of US stocks

Returns & dividend
Return on equity
10.8%

Higher than 64% of US stocks

Return on assets
5.7%

Higher than 79% of US stocks

Dividend yield
0.7%

Higher than 12% of US dividend payers

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • QIAGEN NV has a market value of $10.2B and an enterprise value of $11.1B.

  • Revenue in the twelve months to 30 June 2026: $2.1B. The latest quarter grew 0.3% year on year.

  • Net income over the same four quarters: $409.3M, a 19.5% net margin.

  • Diluted earnings per share, trailing twelve months: $1.98.

  • Free cash flow in the twelve months to 30 June 2026: $440.6M.

  • Shares outstanding: 206.5M.

  • Trailing P/E: 26.7×; forward P/E: 18.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.71%, paying out 19% of earnings.

  • QIAGEN NV employs 5,400 people — $389K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

QGEN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
QGENQIAGEN NV$10.2B92
ICLRICON plc$14.3B75
CRLCharles River Laboratories International, Inc.$15.5B87
RVTYRevvity, Inc.$16.2B97
MEDPMedpace Holdings, Inc.$17.4B93
GHGuardant Health, Inc.$18.9B46
RDNTRadNet, Inc.$5.4B43

Take a look at QGEN’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own QIAGEN NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about QGEN

What is the QGEN stock price forecast for 2026-2027?

The 12 Wall Street analysts covering QIAGEN NV have a median 12-month price target of $52, with estimates ranging from $40 to $53. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QGEN stock a buy right now?

Of the 12 analysts covering QIAGEN NV, 1 rate it a Buy, 11 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks QIAGEN NV 92 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QGEN?

As at 21 Nov 2026, QIAGEN NV ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will QGEN stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +5.5% from the last close, and Ticker Nerd's factor model ranks QIAGEN NV 92 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QGEN stock forecast for 2030?

No analyst covering QIAGEN NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $53 over the next 12 months.

How has QGEN stock performed over the past year?

QIAGEN NV returned +8.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does QIAGEN NV do?

Qiagen N.V. is a biotechnology company that provides Sample to Insight solutions for molecular diagnostics, applied testing, academic research, and pharmaceutical research. Qiagen develops and markets sample preparation products, assay technologies, instruments, and bioinformatics software that help customers isolate, process, and analyze DNA, RNA, and proteins from biological materials.

Company

About QIAGEN NV.

Qiagen N.V. is a biotechnology company that provides Sample to Insight solutions for molecular diagnostics, applied testing, academic research, and pharmaceutical research. Qiagen develops and markets sample preparation products, assay technologies, instruments, and bioinformatics software that help customers isolate, process, and analyze DNA, RNA, and proteins from biological materials. Its portfolio supports workflows in areas such as genotyping, gene expression, viral and bacterial analysis, next-generation sequencing, forensic testing, and clinical decision support. The company serves laboratories, healthcare organizations, research institutions, and life science companies worldwide, making it a key supplier in molecular testing and research workflows. Qiagen N.V. is headquartered in Venlo, the Netherlands, with major operational activities in Hilden, Germany.

CEO Mr. Jonathan M. Pratt · 5,400 employees · Netherlands · https://www.qiagen.com